© 2026 Hashnode
In March 2025, Dr. Nora Volkow a leading voice in addiction research argued that we’re shifting how success is measured: “reduction of drug use” is being advanced as a valid endpoint in treatment trials, not just total abstinence. That’s a humble but...

The short answer is: there’s no one-size-fits-all “magic pill.” But the science is evolving, and new possibilities are emerging. Let’s walk through where we are now and where we might be headed. Starting from a recent study: GLP-1 drugs and addiction...

In a groundbreaking 2025 randomized trial, researchers found that once-weekly semaglutide a medication originally developed for diabetes and obesity “reduced weekly alcohol craving relative to placebo” and led to measurable declines in alcohol consum...

“Now, the FDA accepts reduction in use as a valid clinical outcome” opening new doors for treatments where total abstinence isn’t always immediately realistic. In a small human trial, Ozempic users reduced their alcohol craving and drank significantl...

“Providing incentives for \*treatment participation and negative drug tests is the most effective treatment we have for methamphetamine and cocaine addictions.”— Dr. Nora Volkow, National Institute on Drug Abuse [(NIDA)](https://nida.nih.gov/about-ni...

A recent report from the National Institute on Drug Abuse (NIDA) highlights that addiction remains one of the most complex public health challenges in the United States, affecting millions of lives across all demographics. Among its findings, the rep...

A recent study published by the Centers for Disease Control and Prevention (CDC) reveals a sobering fact: nearly one in six adults binge drinks, with almost a quarter of those episodes occurring at levels considered “high intensity,” twice the level ...

When it comes to addressing drug and alcohol use, timing and approach can make all the difference. A brief intervention is a powerful, evidence-based strategy designed to motivate individuals to change risky substance use behaviors before they escala...
